Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

Juurinen, Leena; Kotronen, Anna; Granér, Marit; Yki‐Järvinen, Hannele

doi:10.1210/jc.2007-1825

Cited by 50 publications

(38 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast to metformin, TZDs improve whole-body insulin sensitivity during hyperinsulinemic-euglycemic clamp studies in patients with T2DM [93,94], reflecting an increase in peripheral glucose disposal. Although both metformin and TZDs decrease hepatic glucose production, only TZDs decrease liver fat content [93,95]. The partitioning of lipids to WAT (i.e., "lipid steal" hypothesis) following TZD treatment likely accounts for the indirect improvement in skeletal muscle insulin sensitivity and the reduction in liver steatosis, similar to what is seen in animal models.…”

Section: Insulin Sensitizers: Metformin and Thiazolidinedionesmentioning

confidence: 88%

Congenital Lipodystrophies and Dyslipidemias

Prieur

May

Magré

et al. 2014

Curr Atheroscler Rep

View full text Add to dashboard Cite

Lipodystrophies are rare acquired and genetic disorders characterized by the selective loss of adipose tissue. One key metabolic feature of patients with congenital inherited lipodystrophy is hypertriglyceridemia. The precise mechanisms by which the lack of adipose tissue causes dyslipidemia remain largely unknown. In recent years, new insights have arisen from data obtained in vitro in adipocytes, yeast, drosophila, and very recently in several genetically modified mouse models of generalized lipodystrophy. A common metabolic pathway involving accelerated lipolysis and defective energy storage seems to contribute to the dyslipidemia associated with congenital generalized lipodystrophy syndromes, although the pathophysiological changes may vary with the nature of the mutation involved. Therapeutic management of dyslipidemia in patients with lipodystrophy is primarily based on specific approaches using recombinant leptin therapy. Preclinical studies suggest a potential efficacy of thiazolidinediones that remains to be assessed in dedicated clinical trials.

show abstract

Section: Insulin Sensitizers: Metformin and Thiazolidinedionesmentioning

confidence: 88%

Congenital Lipodystrophies and Dyslipidemias

Prieur

May

Magré

et al. 2014

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

“…In diabetic patients, any type of treatment may modify the natural state of insulin action and/or secretion, unless the patient is studied at diagnosis before institution of any therapy or unless treatment is discontinued for prolonged periods, neither of which is ethically acceptable. However, the scientific literature, replete with such experiments that have the same limitations, has remarkably advanced our understanding of the pathophysiological changes in insulin action and secretion in T2DM and their modulations with various therapeutic approaches (36,37). Also, diabetics with an HbA1C above 8.5% were not studied, and it is possible that the strength of the correlations between surrogate indices may vary with the level of glycemic control.…”

Section: Discussionmentioning

confidence: 99%

Surrogate Estimates of Insulin Sensitivity in Obese Youth along the Spectrum of Glucose Tolerance from Normal to Prediabetes to Diabetes

George

Bacha

Lee

et al. 2011

The Journal of Clinical Endocrinology & Metabolism

109

106

View full text Add to dashboard Cite

show abstract

“…gov Identifier: NCT00063635). Also, thiazolidinediones, such as pioglitazone and rosiglitazone, have been used successfully for improving insulin resistance and possibly liver histology in adults, but their use in children still requires an accurate control study before they can be considered for use in clinical practice [53][54][55] .…”

Section: Insulin Sensitizersmentioning

confidence: 99%

Pediatric non-alcoholic fatty liver disease: Preventive andtherapeutic value of lifestyle intervention

Nobili¹,

Alisi²,

Raponi³

2009

WJG

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), and eventually cirrhosis and liver failure, is seen to be increasing amongst Western children. NAFLD rates are rising in parallel with the epidemic of childhood obesity, and in particular, fatty liver evolves more easily in NASH when poor dietary habits and sedentary lifestyle are combined. In fact, its general prevalence in the child population varies between 2.6% and 10%, but increases up to 80% in obese children. Since NASH is expected to become the most common cause of pediatric chronic liver disease in the near future, there is broad interest amongst clinical researchers to move forward, both in diagnosis and treatment. Unfortunately, to date, the expensive and invasive procedure of liver biopsy is seen as the gold standard for NASH diagnosis and few noninvasive diagnostic methods can be applied successfully. Moreover, there are still no approved pharmacological interventions for NAFLD/NASH. Therefore, current management paradigms are based upon the presence of associated risk factors and aims to improve an individual's quality of life, thus reducing NAFLD-associated morbidity and mortality. Today, lifestyle intervention (diet and exercise) is the treatment of choice for NAFLD/ NASH. Thus far, no study has evaluated the potential preventive effect of lifestyle intervention on children at risk of NAFLD/NASH. Future studies will be required in this area with the perspective of developing a national program to promote nutrition education and increase physical activity as means of preventing the disease in individuals at risk. Here, we outline the clinical course, pathogenesis and management of NAFLD in children, highlighting the preventive and therapeutic value of lifestyle intervention.

show abstract

Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

Cited by 50 publications

References 55 publications

Congenital Lipodystrophies and Dyslipidemias

Congenital Lipodystrophies and Dyslipidemias

Surrogate Estimates of Insulin Sensitivity in Obese Youth along the Spectrum of Glucose Tolerance from Normal to Prediabetes to Diabetes

Pediatric non-alcoholic fatty liver disease: Preventive andtherapeutic value of lifestyle intervention

Contact Info

Product

Resources

About